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Abstract
Background: Osteocraniostenosis (OCS) is a rare genetic disorder characterised by premature closure of cranial
sutures, gracile bones and perinatal lethality. Previously, diagnosis has only been possible postnatally on clinical and
radiological features. This study describes the first prenatal diagnosis of OCS.
Case presentation: In this case prenatal ultrasound images were suggestive of a serious but non-lethal skeletal
dysplasia. Due to the uncertain prognosis the parents were offered Whole Exome Sequencing (WES), which
identified a specific gene mutation in the FAMIIIa gene. This mutation had previously been detected in two cases
and was lethal in both perinatally. This established the diagnosis, a clear prognosis and allowed informed parental
choice regarding ongoing pregnancy management.
Conclusions: This case report supports the use of targeted WES prenatally to confirm the underlying cause and
prognosis of sonographically suspected abnormalities.
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Background
Osteocraniostenosis (OCS) was first described in 1994
and was noted to be a perinatally lethal condition with
premature closure of cranial sutures and gracile bones
[1]. OCS is allelic to the less severe Kenny Caffey syn-
drome (KCS), which is also characterised by impaired
skeletal development with small, thin skeletal bones, in-
creased bone density and hypocalcaemia. KCS and OCS
are caused by heterozygous mutations in the FAMIIIA
gene [2].
Previously, OCS has only been diagnosed postnatally
with a combination of typical dysmorphic features, pres-
ence of hypocalcaemia and radiological features [3].
Here, we describe the first prenatal diagnosis of OCS.
Case presentation
A non-consanguineous couple, who both had healthy
children with previous partners, presented during their
first pregnancy. The first trimester scan was normal and
combined screening showed low risk for a major
chromosomal abnormality. The 20-week ultrasound scan
identified shortened long bones and an unusual skull
shape (Fig. 1). Following a normal detailed chromosome
analysis by Comparative Genomic Hybridisation, the
couple were referred to clinical genetics.
A cloverleaf skull is often associated with OCS. A sub-
sequent ultrasound scan confirmed an unusual skull
shape; however the features were not consistent with a
typical cloverleaf skull. All the long bones were shown
to be 5 Standard deviations (SD) below the mean and
the head and abdominal circumference were 2 SD below
the mean. The ultrasound images did not support a
diagnosis of Diastrophic Dysplasia. While the images
suggested possible curving of both radii and bilateral
Hitchhiker’s thumb, ear morphology was normal and no
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talipes (club foot) was identified. The findings were sug-
gestive of a skeletal dysplasia without a narrow chest or
fetal hydrops, therefore a lethal skeletal dysplasia was
not initially suspected. The couple were counselled
about the uncertainty of the child’s prognosis and of-
fered targeted whole exome sequencing (WES).
Trio exome sequencing was performed with parental
DNA and the stored fetal DNA extracted from the am-
niotic fluid at 21 weeks. Targeted WES was performed
using the Agilent Clinical Research Exome Version 2 &
sequencing on the Illumina NextSeq500. This took 15
days and identified a de novo mutation in FAMIIIA. The
mutation identified, c.1026_1028delTTC p.(ser343del),
has previously been identified in two unrelated male pa-
tients with Osteocraniostenosis [ 4]. In both cases, the
mutation was lethal within the first month of life and as-
sociated with thin dense bones with poor bone marrow
formation.
Targeted WES accurately diagnosed a lethal skeletal
dysplasia that had not been suspected from the ultra-
sound features. This provided essential prognostic infor-
mation and allowed parental choice regarding further
pregnancy management. Following the lethal skeletal
dysplasia diagnosis, the couple made the difficult deci-
sion to end the pregnancy. The postnatal 3D CT scan
confirmed the skeletal abnormalities that were detected
in the prenatal ultrasound. (Fig. 2).
Discussion and conclusion
Prenatal diagnosis helps guide parents and healthcare
professionals regarding pregnancy management deci-
sions, delivery options and postnatal treatment [5].The
introduction of next generation sequencing has expo-
nentially changed the ability to definitively diagnose
monogenic diseases caused by de novo and recessive
mutations. Approximately 1–2% of the human genome
encodes the exome but it is thought to contain more
than 85% of all disease causing mutations [5].
Currently there is not an identifiable syndrome associ-
ated with mutations in all genes. Therefore, in the clin-
ical setting, targeted WES is used. This limits analysis to
those genes that have mutations compatible with the
phenotype identified on ultrasound. Prenatal WES relies
on this sonographic evidence to help select the most ap-
propriate Human Phenotypic Ontology (HPO) terms in
order to target the analysis appropriately. Despite ad-
vances in ultrasound, accurate prenatal diagnosis is lim-
ited to those syndromes with a characteristic phenotype
such as thanatophoric dysplasia and achondroplasia.
Whole Exome Sequencing (WES) has frequently been
used postnatally to diagnose rare syndromes however ex-
perience with prenatal WES remains limited. Analysis
and interpretation of the exome data has been too slow
to be helpful in the prenatal setting, which requires rapid
results. Recent publications such as the PAGE study
2019 and Petroski et al. 2019 have confirmed the
Fig. 1 Ultrasound images demonstrate abnormal skull shape with
open cranial sutures at 20 weeks gestation
Fig. 2 Post delivery CT images confirming short thin gracile bones
and the abnormal skull with basal cranialstenosis
Pemberton et al. BMC Medical Genetics            (2020) 21:7 Page 2 of 3
diagnostic potential of prenatal exome sequencing [6, 7].
The majority of cases reported thus far have only reported
the results after the pregnancy [8]. The introduction of
rapid targeted exome sequencing with results available
within 3 weeks allows for prenatal management.
One of the concerns raised by the use of WES is the
potential for secondary findings. These are genetic vari-
ants that are not related to the phenotype in question,
such as finding cancer susceptibility gene mutations
when looking for genes associated with skeletal dyspla-
sia. Interpretation of secondary findings are not always
clear and can lead to ethical dilemmas in further coun-
selling [9] . The use of targeted WES using phenotypic
gene panels not only significantly reduces incidental/ sec-
ondary findings but also accelerates data interpretation
[10]. In this case, no secondary findings were identified as
only genes associated with skeletal abnormalities were ex-
amined. It was explicit in the consent that we would not
find or report incidental findings.
WES is a powerful tool for accurate prenatal diagnosis,
but it must be done after the 2nd trimester ultrasound.
If a 2nd trimester ultrasound is performed at 20–22
weeks gestation and the WES results take 3 weeks, then
the prenatal choices may be limited for couples who live
in countries with more stringent pregnancy termination
laws. For WES to be used successfully, good phenotyp-
ing is essential. This requires close co-operation between
genetics and fetal medicine.
The diagnosis of OCS is currently made in the postna-
tal period by gross exam and imaging. We used targeted
WES to achieve the first reported case of a prenatal
diagnosis of OCS. This demonstrates that, when the
prognosis of a fetus is uncertain, the prenatal targeted
WES could be used as a tool to help with management
and treatment decisions.
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